Search Results for "ciclesonide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for ciclesonide. Results 11 to 14 of 14 total matches.
See also: Omnaris, Zetonna

Fluticasone Furoate (Veramyst) for Allergic Rhinitis

   
The Medical Letter on Drugs and Therapeutics • Nov 05, 2007  (Issue 1273)
-2 sprays/ 92.53 (AstraZeneca) (32 mcg/spray) 1x/d nostril 1x/d Ciclesonide – Omnaris 2 Metered ...
Fluticasone furoate nasal spray (Veramyst - GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray (Flonase, and others), which is now available generically.
Med Lett Drugs Ther. 2007 Nov 5;49(1273):90-2 |  Show IntroductionHide Introduction

Comparison Chart: Correct Use of Inhalers for Asthma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2024  (Issue 1716)
/salmeterol) ▶ Alvesco (ciclesonide) ▶ Asmanex HFA (mometasone) ▶ Atrovent HFA (ipratropium) ▶ Breyna ...
View the Comparison Chart: Correct Use of Inhalers for Asthma
Med Lett Drugs Ther. 2024 Nov 25;66(1716):e196-8   doi:10.58347/tml.2024.1716c |  Show IntroductionHide Introduction

Comparison Table: Inhaled Drugs for Treatment of COPD (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 2024  (Issue 1710)
, 180 mcg/inh DPI (60, 120 inh/unit) 180-720 mcg bid 248.20 Ciclesonide – Alvesco (Covis) 80, 160 mcg ...
View the Comparison Table: Inhaled Drugs for Treatment of COPD
Med Lett Drugs Ther. 2024 Sep 2;66(1710):e143-7   doi:10.58347/tml.2024.1710b |  Show IntroductionHide Introduction

Treatment of Allergic Rhinitis and Allergic Conjunctivitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025  (Issue 1725)
sprays per 19.4012 (32 mcg/spray) nostril once/day9,10 nostril once/day9,11 Ciclesonide – Omnaris ...
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56   doi:10.58347/tml.2025.1725a |  Show IntroductionHide Introduction